

## Invitation from Michael Scherz and Naheed Mirza, Co-Chairs at Pain Therapeutics 2021

SMi Reports: Co-chairs of the conference Michael Scherz and Naheed Mirza invitation to join SMi's 21st Annual Pain Therapeutics Virtual Conference, 10-11 May.

LONDON, GREATER LONDON, UNITED KINGDOM, March 18, 2021 /EINPresswire.com/ -- It is with great pleasure that co-chairs of the conference, Michael Scherz, Founder and CEO, Metys Pharma and Naheed



Mirza, Early Development Pain and CNS Specialist, invite experts to join the <u>21st Annual Pain</u> <u>Therapeutics Conference</u>, taking place on 10th and 11th May 2021 as a virtual conference with online access only.

The <u>2-day agenda will bring together</u> expertise from individuals in multiple disciplines in the field and offer a series of presentations through which attendees will gain insights into the key drivers of this ever-growing industry. Hear from Notified Bodies and Industry experts on a wide variety of topics

Interested parties can attend the conference at £999 for vendors and commercial firms and £499 for pharmaceutical and biotechnology firms on <a href="http://www.pain-therapeutics.co.uk/PR3">http://www.pain-therapeutics.co.uk/PR3</a>.

Proudly sponsored by <u>MD Biosciences and Transpharmation</u>, the event will bring together expertise from individuals in multiple disciplines in the field and offer a series of presentations that will provide exclusive insights into the key drivers of this ever-growing industry.

An excerpt of the co-chair's invitation to the conference below:

"Now in its 21st year, we have witnessed significant growth within the Pain Therapeutics field ... With new advancements in therapeutic targets for the development of more effective drugs, delegates stand to gain many valuable insights from this event such as:

- •Discovering which innovative new therapies are driving clinical development including Novaremed's work in developing NRD.E1 for diabetic neuropathic pain and Vapogenix's work in developing volatile anaesthetics to treat inflammatory pain
- •Examining the best strategies to generate more funding into pain research clinical trials to eliminate the issue of under funding
- •Exploring how COVID-19 has changed the experience of clinical trials and presented an opportunity to reform the way we approach data verification, data analysis and data collection
- Understanding the role of biomarkers in evaluating target engagement of new drugs and predicting analgesic efficacy"

Attendees will also be able to gain from SMi's virtual conference platform. This will include access to live and on demand speaker content, ability to network with all the event attendees and, hosting and joining meetings and socials with built in Zoom functionality. Sponsors will exhibit with the virtual conference platform, offering a meet up service, schedule meetings, read their articles/documents and what sponsor videos.

As Europe's leading pain therapeutics conference, which will analyse the latest developments in the field of pain drug development, this is a must-attend for those wanting to learn how the industry is working to overcome the challenges of opioid base treatment.

The full agenda, speaker line-up and brochure can be viewed online at: <a href="http://www.pain-therapeutics.co.uk/PR3">http://www.pain-therapeutics.co.uk/PR3</a>

Proudly sponsored by: Transpharmation and MD Biosciences

To join Pain Therapeutics Conference as a sponsor/exhibitor, please get in touch with Alia Malick, Director on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk

SMi's 21st Annual Pain Therapeutics Conference 10 – 11 May 2021 Virtual Conference: Online Access Only <a href="http://www.pain-therapeutics.co.uk/PR3">http://www.pain-therapeutics.co.uk/PR3</a> #SMiPain

--- END---

## About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion

leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <a href="http://www.smi-online.co.uk">http://www.smi-online.co.uk</a>

Simi Sapal SMi Group +442078276000 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/537068740

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.